Incredible gesture of generosity, DHEA for LFOR and more - December 2016 VOICE Digest
November was a highly eventful month here at CHR. Our IVF unit, finally, moved into its new quarters in the new building addition, which has been under construction for almost two years. And all of this happened while we also over four days hosted in association with The Foundation for Reproductive Medicine an international conference on Translational Reproductive Biology and Clinical Reproductive Endocrinology at the Grand Hyatt Hotel here in Manhattan, which attracted over 250 participants from all over the world to exceptional reviews. The Conference, indeed, was so successful that it was decided to make it an annual event here in New York City, with the next one already scheduled for November 16-19, 2017. The two mottos for the Conference remain the same: “Think differently!” and “Christmas shopping for new knowledge in New York City.”
We are looking forward to completing all construction at CHR by February, and will then have at our disposition a truly state-of-the arts clinical, research and educational facility, which will be able not only to accommodate our patients from all over the world but also the ever increasing numbers of colleagues from all over the world who are visiting CHR to familiarize themselves with CHR’s clinical management of complex patients.
This last 2016 issue of the CHR VOICE will feature as its lead article an update on one of the principle innovations CHR has contributed to modern infertility treatments, namely androgen hormone supplementation in the form of dehyroepiandrosterone (DHEA) to women with low functional ovarian reserve (LFOR). Twelve years ago, Drs. Barad and Gleicher started DHEA supplementations of women with LFOR at CHR, and it is 11 years since they published the first paper on this treatment [Barad DH, Gleicher N Increased oocyte production after treatment with dehydroepiandrosterone. Fertil Steril 2015;84(3)756], reporting on the then incredulous increase in egg and embryo production an older woman achieved who, on her own, had started supplementing herself with DHEA. Now, more than a decade later, androgen supplementation has become common practice all over the world, and the time appears opportune to offer an update.
Finally, we also want to take the opportunity to wish all of our patients, colleagues and other readers a wonderful Holiday Season and a Happy, Healthy and Prosperous New Year, and are looking forward to welcoming you back a readers of the VOICE in 2017.
In this VOICE, we cover:
- An incredible story of generosity that brought us to tears
- DHEA for women with low functional ovarian reserve
- Staff Spotlight: Nicolas Santiquet, PhD
- In Focus
Read this issue in PDF.
Norbert Gleicher, MD, leads CHR’s clinical and research efforts as Medical Director and Chief Scientist. A world-renowned specialist in reproductive endocrinology, Dr. Gleicher has published hundreds of peer-reviewed papers and lectured globally while keeping an active clinical career focused on ovarian aging, immunological issues and other difficult cases of infertility.
We have helped women bring over 17,800 babies into the world.Discover your treatment options
- Breaking News in ScienceLetter to President Biden and Secretary Designate of HHS, Xavier Becerra In a published letter (Santoro et al Reprod Sciences 2021; https:/doi.org/10.1007/s43032-021-00491-9), a
- More On COVID-19DOES THE BRITISH STRAIN B.1.1.7 INCREASE MORTALITY OVER D614G? A just published study by British investigators claims that not only infectivity of the
- Mild Ovarian StimulationTwo prominent voices in the fertility field known as longstanding supporters of mild ovarian stimulation were at it once again (Nargund and Fauser, Reprod Biomed Online 2020;41:569-571) when
- Brief Case Studies in Clinical InfertilityIs there a place for DHEA and CoQ10 in women undergoing “planned” egg-freezing? At CHR, women undergoing egg-freeing cycles undergo a very